Secondary resistance to cabergoline therapy in a macroprolactinoma: A case report and literature review

Pituitary

Volumn 14, Issue 4, 2011, Pages 362-366

  Behan, L A ^a   Draman, M S ^a   Moran, C ^a   King, T ^a   Crowley, R K ^a   O'Sullivan, E P ^a   Smith, D ^a   Thompson, C J ^a   Agha, A ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Dopamine therapy; Prolactinoma; Secondary resistance

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; PROLACTIN;

ADULT; CASE REPORT; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FEMALE; GROWTH HORMONE DEFICIENCY; HEMIANOPIA; HISTOPATHOLOGY; HUMAN; INSULIN TOLERANCE TEST; LONG TERM CARE; NAUSEA; NERVE COMPRESSION; OPTIC CHIASM; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR RESISTANCE; VAGINA BLEEDING; VAGINAL HYSTERECTOMY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG TOLERANCE; ERGOLINES; FEMALE; HUMANS; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 79955082173     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-009-0168-0     Document Type: Review

References (12)

1. MP Gillam ME Molitch G Lombardi A Colao 2006 Advances in the treatment of prolactinomas Endocr Rev 27 485 534 10.1210/er.2005-9998 16705142 10.1210/er.2005-9998 1:CAS:528:DC%2BD28XpvVelurY%3D (Pubitemid 44213229)
2. J Webster 1996 A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation Drug Saf 14 228 238 10.2165/00002018-199614040-00003 8713691 10.2165/00002018-199614040-00003 1:CAS:528:DyaK28Xis1Slsbs%3D (Pubitemid 26128812)
3. ME Molitch 2005 Pharmacologic resistance in prolactinoma patients Pituitary 8 43 52 10.1007/s11102-005-5085-2 16411068 10.1007/s11102-005-5085-2 1:CAS:528:DC%2BD28XksVOgtw%3D%3D (Pubitemid 44680085)
4. T Brue I Pelligrini A Priou, et al. 1992 Prolactinomas and resistance to dopamine agonists Horm Res 38 84 89 10.1159/000182496 1306523 10.1159/000182496 1:CAS:528:DyaK3sXkvVGmsb8%3D (Pubitemid 23163259)
5. K Kovacs L Stefaneanu E Hovarth 1995 Prolactin producing pituitary tumour: resistance to dopamine agonist therapy J Neurosurg 82 886 890 7714616 10.3171/jns.1995.82.5.0886 1:STN:280:DyaK2M3jtVersA%3D%3D
6. M Kars F Roelfsema A Romijin AM Pereira 2006 Malignant prolactinoma: case report and review of the literature Eur J Endocrinol 155 523 534 10.1530/eje.1.02268 16990651 10.1530/eje.1.02268 1:CAS:528:DC%2BD28XhtFKjtb%2FF (Pubitemid 44636871)
7. D Dallabonzana B Spelta G Oppizzi, et al. 1983 Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases J Endocrinol Invest 6 47 50 6841916 1:STN:280:DyaL3s7oslCnsA%3D%3D (Pubitemid 13128004)
8. H Breidahl D Topliss JW Pike 1983 Failure of bromocriptine to maintain reduction in size of a macroprolactinoma Br Med J (Clin Res Ed) 287 451 452 10.1136/bmj.287.6390.451 1:STN:280:DyaL3s3osVWisg%3D%3D (Pubitemid 13028269)
9. E Delgrange J Crabbe J Donickier 1998 Late development if resistance to bromocriptine in a patient with macroprolactinoma Horm Res 49 250 253 10.1159/000023180 9568811 10.1159/000023180 1:CAS:528:DyaK1cXisVensL0%3D (Pubitemid 28165744)
10. D McCall SJ Hunter RS Cooke B Herron, et al. 2007 Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associate with transition from micro to macroadenoma Clin Endocrinol (Oxf) 66 149 150 1:STN:280:DC%2BD2s%2Fgs1ersw%3D%3D (Pubitemid 44952509)
11. L Caccavelli F Feron I Morange, et al. 1994 Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas Neuroendocrinology 60 3 314 322 10.1159/000126764 7969790 10.1159/000126764 1:CAS:528:DyaK2cXlvFGhtLw%3D
12. C Missale M Losa S Sigala, et al. 1996 nerve growth factor controls proliferation and progression of human prolactinoma cell lines through autocrine mechanism Mol Endocrinol 10 3 272 285 10.1210/me.10.3.272 8833656 10.1210/me.10.3.272 1:CAS:528:DyaK28XhsFyis7c%3D (Pubitemid 26082699)